Market Research Logo


FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

483 Reports from FirstWord

  • Multiple Sclerosis: Update Bulletin #1 [February 2018]

    ... been approved by the European Commission as a treatment for RRMS and PPMS; Mylan announcing the UK launch of Brabio (glatiramer acetate injection; 40 mg/ml), a generic version of Copaxone; as well as Merck KGaA’s ... Read More

  • Systemic Lupus Erythematosus (SLE): Update Bulletin #2

    ... prospects of the Phase III BLISS-BELIEVE study which will assess co-administration of SC Benylsta (GSK’s belimumab) and a single cycle of IV Rituxan/MabThera (rituximab; Roche/Biogen). The KOLs also imparted their views on the results of ... Read More

  • NPS+ HIV (EU5) 2018

    ... achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ HIV (EU5) ... Read More

  • Targeted Therapies in Asthma: KOL Insight [2018]

    ... to use currently approved treatments, including Xolair, Nucala and Cinqair/Cinqaero, and which treatments offer the best for patients. Visible on the horizon is another anti-IL-5 mAb, AstraZeneca’s Fasenra (benralizumab), and by all accounts KOLs believe ... Read More

  • MSL Teams: Field force size and structure

    ... stakeholder groups. The challenge for senior management is to ensure their MSL teams are optimally provided for in terms of staff and resources. But what is optimum? What are the factors that determine MSL team ... Read More

  • Acute Myeloid Leukaemia:KOL Insight

    ... four new therapies for AML; Novartis’ Rydapt, Celgene/Agios’ Idhifa, Jazz Pharma’s Vyxeos and Pfizer’s Mylotarg. How are these agents faring on the market so far and will more personalised treatments follow their lead? AbbVie/Roche’s Venclexta/Venclyxto ... Read More

  • Glioblastoma: KOL Insight

    ... into late-stage development, but what chances do these programmes have in reaching the market? Learn how KOLs see the glioblastoma market evolving in Glioblastoma: KOL Insight (2018). Twelve US and European KOLs provide candid insights ... Read More

  • NPS+ Haemophilia B (US) 2018

    ... are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ Haemophilia ... Read More

  • COPD: Update Bulletin

    ... pulmonary disease (COPD) market, including; Theravance and Mylan announcing the submission of a New Drug Application (NDA) for the once-daily, nebulised, long-acting muscarinic antagonist (LAMA) revefenacin, to the US FDA; Novartis announcing positive results from ... Read More

  • Alzheimer’s Disease: Update Bulletin [January 2018]

    ... and Amgen, together with the Banner Alzheimer’s Institute, launching a new Phase II/III study with beta-secretase-1 inhibitor, CNP520 in an asymptomatic, high-risk population; IntelGenx initiating a Phase IIa study of Montelukast VersaFilm for patients with ... Read More

  • Pricing and Reimbursement in Oncology -- Payer views

    ... is not sustainable or winning pharma any friends. In this expert report, US and EU payers note that monopolistic pricing for novel products that represent the only therapeutic option, or the high prices demanded for ... Read More

  • Ambitions in Health: Tech companies step up the pace

    ... tech giants are leveraging the latest advances in artificial intelligence (AI), deep learning, analytics and wearable technology to drive innovation and disrupt processes. How can pharma respond and what strengths does it have that tech ... Read More

  • Charting the Global Biosimilar pipeline

    ... Co's Remicade (infliximab) are being targeted by multiple biosimilar developers. But which companies are leading the market? What products are being targeted? Where is development geographically concentrated? What licensing and collaboration opportunities are there? The ... Read More

  • Prostate Cancer: Update Bulletin [January 2018]

    ... Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS); the European Commission’s extended approval for Johnson & Johnson’s (J&J’s) Zytiga ... Read More

  • Ovarian Cancer: Update Bulletin [January 2018]

    ... for Avastin (bevacizumab) and chemotherapy, followed by Avastin alone, in the front-line setting; EU approval of Zejula (niraparib; Tesaro/Merck & Co.) for the treatment of recurrent ovarian cancer, irrespective of BRCA mutation or biomarker status; ... Read More

  • Pricing and Reimbursement in Neurology -- Payer views

    ... it. So, just how serious a stumbling block is the price gap between old and new proving to be for payers in the US and EU? Are pharma's pricing justifications believed and accepted? And what ... Read More

  • RCC [2017]: Bulletin #2

    ... Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with ipilimumab (Yervoy), in intermediate- and poor-risk patients with previously untreated advanced or metastatic RCC; the European Medicines Agency (EMA) approval of AVEO Oncology’s Fotivda (tivozanib) in advanced RCC; ... Read More

  • Ulcerative Colitis: Update Bulletin #1

    ... (vedolizumab); Qu Biologics reporting that QBECO achieved high clinical and endoscopic response ratesin a Phase II trial conducted in patients with moderate-to-severe UC; Protagonist Therapeutics announcing the initiation of dosing in a Phase I study ... Read More

  • Atopic Dermatitis: Update Bulletin #1

    ... announcement of results from an 8-week randomised Phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis; Sanofi and Regeneron’s announcement of positive results from ... Read More

  • Rheumatoid Arthritis: Update Bulletin #3

    ... the European Commisssion had granted approval for the company’s adalimumab biosimilar, Cyltezo; the FDA’s acceptance of a regulatory submission for Sandoz’s rituximab biosimilar (GP2013), marketed in Europe as Rixathon/Riximyo since June 2017; and Celltrion’s development ... Read More

  • Cystic Fibrosis: Update Bulletin #3

    ... EMAfor tezacaftor/ivacaftor, a second-in-class cystic fibrosis transmembrane conductance regulator (CFTR), which has been granted Priority Review status in the US; ProQR Therapeutics’ publication of positive preliminary results from a Phase 1b study assessing QR-010,a novel ... Read More

  • Colorectal Cancer: Update Bulletin #1

    ... Symphogen announcing detailed results from its randomised Phase II study with SYM004 compared to investigator-choice chemotherapy or best-supportive-care, in patients with advanced metastatic CRC and acquired resistance to anti-EGFR monoclonal antibodies (mAbs); Array BioPharma and ... Read More

  • Type 2 Diabetes Mellitus: Update Bulletin #1

    ... of the Phase IIIb/IV EXSCEL study which is assessing the cardiovascular (CV) risk of AstraZeneca’s Bydureon (exenatide extended release) in T2DM patients; and views on Zafgen’s ZGN-1061, a fumagillin-class, injectable small molecule second generation MetAP2 ... Read More

  • Multiple Myeloma: Update Bulletin #2

    ... (Kyprolis) administered once-weekly at the 70 mg/m2 dose with dexamethasone in rrMM patients; FDA’s partial clinical hold suspending patient recruitment in three studies of BMS’ nivolumab (Opdivo)-based combinations in rrMM: CheckMate-602, CheckMate-039 and CA204142; and ... Read More

  • The ROI of Orphan Drugs-- Ensuring optimal returns (2017)

    ... lives; there's also the lure of potentially lucrative commercial benefits for those that succeed. But finding the right balance between return on investment (ROI) and optimum patient access is proving difficult. And with only 415 ... Read More

1 2 4 6 7 8 9 10

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook